Skip to main content

Advertisement

Table 3 Comparison of patients that reported being much improved and those reporting less positive results after completing 3 years of Grazax treatment (n (%))

From: Sublingual grass allergen specific immunotherapy: a retrospective study of clinical outcome and discontinuation

Allergic symptoms had much improved during the latest grass pollen season compared to the season before you started using
  Yes
(n = 55)
No
(n = 52)
p-value
Female 24 (45%) 29 (56%) 0.21
Age 42 ± 11 40 ± 11 0.39
Other allergies 35 (65%) 42 (81%) 0.06
Asthma 18 (33%) 29 (56%) 0.02
Year since treatment completion 3.5 ± 2.2 3.1 ± 2.3 0.36